Piotr L.
- Country
- Poland
- Department
- Oddział IV Alergologiczny
Research Overview
- Long-term safety and efficacy of subcutaneous lunsekimig in adults with asthma: An open-label extension study
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- Phase III Open‑Label Study of Subcutaneous Benralizumab in Children with Eosinophilic Disease: Safety, PK/PD, Efficacy and Immunogenicity
Data & Insights
Has run more than one trial at 178 of 525 partner sites.
Specializations
Asthma and Severe Asthma
Piotr Łacwik is involved in clinical research centered on asthma, including mild to moderate asthma, moderate-to-severe asthma, severe and inadequately controlled asthma, and oral corticosteroid-dependent asthma. His work includes evaluation of therapies aimed at improving lung function, reducing exacerbations, and supporting corticosteroid-sparing treatment strategies.
- Inhaled triple therapy
- Biologic therapy for asthma control
- Oral corticosteroid reduction
- Exacerbation prevention
His research activity also covers comparative assessment of inhaled treatments and long-term management options for adults with persistent asthma symptoms.
Chronic Obstructive Pulmonary Disease
Another major area of interest is chronic obstructive pulmonary disease, including moderate to severe COPD, moderate to very severe COPD, and COPD with a history of frequent exacerbations and elevated eosinophils. The clinical focus includes therapies designed to reduce exacerbation burden and improve respiratory outcomes in symptomatic patients.
- COPD exacerbation reduction
- Long-acting bronchodilator combinations
- Inhaled maintenance therapy
- Cardiopulmonary outcomes
His portfolio also includes studies of treatment equivalence and device or formulation comparisons within COPD care.
Hypereosinophilic Syndrome
Piotr Łacwik is active in research on hypereosinophilic syndrome, with attention to uncontrolled disease and flare prevention. This area includes clinical evaluation of biologic approaches targeting eosinophilic inflammation and symptom worsening in patients receiving standard care.
- Eosinophilic inflammation
- Disease flare prevention
- Biologic treatment
- Uncontrolled HES
His involvement supports therapeutic development for a rare inflammatory disorder with significant respiratory and systemic impact.
Comparative inhaled therapy and therapeutic equivalence
His research landscape also includes comparative studies of inhaled respiratory medicines, with emphasis on therapeutic equivalence, lung function outcomes, and safety in adults with obstructive airway disease. These studies span both asthma and COPD settings and include comparisons across formulations and delivery systems.
- Lung function assessment
- Inhaler formulation comparison
- Safety evaluation
- Respiratory maintenance treatment
His work contributes to the clinical assessment of established and emerging inhaled therapies used in chronic respiratory disease.
Biologic and novel anti-inflammatory therapies
Piotr Łacwik is also engaged in studies of newer targeted agents for respiratory and eosinophilic disease, including therapies aimed at reducing exacerbations, improving symptom control, and supporting long-term disease management in adults with asthma and COPD.
- Targeted anti-inflammatory treatment
- Exacerbation control
- Long-term safety
- Advanced respiratory therapeutics
This area reflects involvement in the clinical development of innovative options for chronic airway and eosinophil-driven disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.